Epicatechin limits renal injury by mitochondrial protection in cisplatin nephropathy

American Journal of Physiology - Renal Physiology

Volumn 303, Issue 9, 2012, Pages

  Tanabe, Katsuyuki ^a   Tamura, Yoshifuru ^a   Lanaspa, Miguel A ^a   Miyazaki, Makoto ^a   Suzuki, Norihiko ^b   Sato, Waichi ^b   Maeshima, Yohei ^c   Schreiner, George F ^d   Villarreal, Francisco J ^e   Johnson, Richard J ^a   Nakagawa, Takahiko ^a,f  

^a UNIVERSITY OF COLORADO   (United States)

^b NAGOYA UNIVERSITY   (Japan)

^c OKAYAMA UNIVERSITY   (Japan)

^d Cardero Therapeutics Incorporated   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

AKI; Cocoa; Complex IV; Dark chocolate; MnSOD

Indexed keywords

EID: 84868369214     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00227.2012     Document Type: Article

References (43)

1. Al-Malki AL, Moselhy SS. The protective effect of epicatchin against oxidative stress and nephrotoxicity in rats induced by cyclosporine. Hum Exp Toxicol 30: 145-151, 2011.
2. Arany I, Safirstein RL. Cisplatin nephrotoxicity Semin Nephrol 23: 460-464, 2003.
3. Barsoum MJ, Yuan H, Gerencser AA, Liot G, Kushnareva Y, Graber S, Kovacs I, Lee WD, Waggoner J, Cui J, White AD, Bossy B, Martinou JC, Youle RJ, Lipton SA, Ellisman MH, Perkins GA, Bossy-Wetzel E. Nitric oxide-induced mitochondrial fission is regulated by dynamin-related GTPases in neurons. EMBO J 25: 3900-3911, 2006.
4. Brooks C, Cho SG, Wang CY, Yang T, Dong Z. Fragmented mitochondria are sensitized to Bax insertion and activation during apoptosis. Am J Physiol Cell Physiol 300: C447-C455, 2011.
5. Brooks C, Wei Q, Cho SG, Dong Z. Regulation of mitochondrial dynamics in acute kidney injury in cell culture and rodent models. J Clin Invest 119: 1275-1285, 2009.
6. Chowanadisai W, Bauerly KA, Tchaparian E, Wong A, Cortopassi GA, Rucker RB. Pyrroloquinoline quinone stimulates mitochondrial biogenesis through cAMP response element-binding protein phosphorylation and increased PGC-1alpha expression. J Biol Chem 285: 142-152, 2010.
7. Cohen SM, Lippard SJ. Cisplatin: from DNA damage to cancer chemotherapy. Prog Nucleic Acid Res Mol Biol 67: 93-130, 2001.
8. Corti R, Flammer AJ, Hollenberg NK, Luscher TF. Cocoa and cardiovascular health. Circulation 119: 1433-1441, 2009.
9. 2 in cisplatin-induced renal cell apoptosis. J Pharmacol Exp Ther 308: 921-928, 2004.
10. Ernest S, Bello-Reuss E. Expression and function of P-glycoprotein in a mouse kidney cell line. Am J Physiol Cell Physiol 269: C323-C333, 1995.
11. Esposito LA, Melov S, Panov A, Cottrell BA, Wallace DC. Mitochondrial disease in mouse results in increased oxidative stress. Proc Natl Acad Sci USA 96: 4820-4825, 1999.
12. Faubel S, Ljubanovic D, Reznikov L, Somerset H, Dinarello CA, Edelstein CL. Caspase-1-deficient mice are protected against cisplatininduced apoptosis and acute tubular necrosis. Kidney Int 66: 2202-2213, 2004.
13. Fisher ND, Hollenberg NK. Flavanols for cardiovascular health: the science behind the sweetness. J Hypertens 23: 1453-1459, 2005.
14. Fisher ND, Hughes M, Gerhard-Herman M, Hollenberg NK. Flavanolrich cocoa induces nitric-oxide-dependent vasodilation in healthy humans. J Hypertens 21: 2281-2286, 2003.
15. Gomez-Guzman M, Jimenez R, Sanchez M, Zarzuelo MJ, Galindo P, Quintela AM, Lopez-Sepulveda R, Romero M, Tamargo J, Vargas F, Perez-Vizcaino F, Duarte J. Epicatechin lowers blood pressure, restores endothelial function, and decreases oxidative stress and endothelin-1 and NADPH oxidase activity in DOCA-salt hypertension. Free Radic Biol Med 52: 70-79, 2012.
16. Hollenberg NK, Martinez G, McCullough M, Meinking T, Passan D, Preston M, Rivera A, Taplin D, Vicaria-Clement M. Aging, acculturation, salt intake, and hypertension in the Kuna of Panama. Hypertension 29: 171-176, 1997.
17. Hollenberg NK, Rivera A, Meinking T, Martinez G, McCullough M, Passan D, Preston M, Taplin D, Vicaria-Clement M. Age, renal perfusion and function in island-dwelling indigenous Kuna Amerinds of Panama. Nephron 82: 131-138, 1999.
18. Huttemann M, Lee I, Malek MH. (-)-Epicatechin maintains endurance training adaptation in mice after 14 days of detraining. FASEB J 26: 1413-1422, 2012.
19. Jiang M, Wei Q, Wang J, Du Q, Yu J, Zhang L, Dong Z. Regulation of PUMA-alpha by p53 in cisplatin-induced renal cell apoptosis. Oncogene 25: 4056-4066, 2006.
20. Jiang M, Yi X, Hsu S, Wang CY, Dong Z. Role of p53 in cisplatininduced tubular cell apoptosis: dependence on p53 transcriptional activity. Am J Physiol Renal Physiol 287: F1140-F1147, 2004.
21. Kim YK, Kim HJ, Kwon CH, Kim JH, Woo JS, Jung JS, Kim JM. Role of ERK activation in cisplatin-induced apoptosis in OK renal epithelial cells. J Appl Toxicol 25: 374-382, 2005.
22. Kruidering M, Maasdam DH, Prins FA, de Heer E, Mulder GJ, Nagelkerke JF. Evaluation of nephrotoxicity in vitro using a suspension of highly purified porcine proximal tubular cells and characterization of the cells in primary culture. Exp Nephrol 2: 324-344, 1994.
23. Kruidering M, Van de Water B, de Heer E, Mulder GJ, Nagelkerke JF. Cisplatin-induced nephrotoxicity in porcine proximal tubular cells: mitochondrial dysfunction by inhibition of complexes I to IV of the respiratory chain. J Pharmacol Exp Ther 280: 638-649, 1997.
24. Lee RH, Song JM, Park MY, Kang SK, Kim YK, Jung JS. Cisplatininduced apoptosis by translocation of endogenous Bax in mouse collecting duct cells. Biochem Pharmacol 62: 1013-1023, 2001.
25. Li N, Ragheb K, Lawler G, Sturgis J, Rajwa B, Melendez JA, Robinson JP. Mitochondrial complex I inhibitor rotenone induces apoptosis through enhancing mitochondrial reactive oxygen species production. J Biol Chem 278: 8516-8525, 2003.
26. Megyesi J, Udvarhelyi N, Safirstein RL, Price PM. The p53-independent activation of transcription of p21 WAF1/CIP1/SDI1 after acute renal failure. Am J Physiol Renal Fluid Electrolyte Physiol 271: F1211-F1216, 1996.
27. Mukhopadhyay P, Horvath B, Zsengeller Z, Zielonka J, Tanchian G, Holovac E, Kechrid M, Patel V, Stillman IE, Parikh SM, Joseph J, Kalyanaraman B, Pacher P. Mitochondrial-targeted antioxidants represent a promising approach for prevention of cisplatin-induced nephropathy. Free Radic Biol Med 52: 497-506, 2012.
28. Nogueira L, Ramirez-Sanchez I, Perkins GA, Murphy A, Taub PR, Ceballos G, Villarreal FJ, Hogan MC, Malek MH. (-)-Epicatechin enhances fatigue resistance and oxidative capacity in mouse muscle. J Physiol 589: 4615-4631, 2011.
29. Owens DM, Keyse SM. Differential regulation of MAP kinase signalling by dual-specificity protein phosphatases. Oncogene 26: 3203-3213, 2007.
30. Pabla N, Dong Z. Cisplatin nephrotoxicity: mechanisms and renoprotective strategies. Kidney Int 73: 994-1007, 2008.
31. Ramirez-Sanchez I, Maya L, Ceballos G, Villarreal F. (-)-Epicatechin activation of endothelial cell endothelial nitric oxide synthase, nitric oxide, and related signaling pathways. Hypertension 55: 1398-1405, 2010.
32. Ramirez-Sanchez I, Maya L, Ceballos G, Villarreal F. (-)-Epicatechin induces calcium-and translocation-independent eNOS activation in arterial endothelial cells. Am J Physiol Cell Physiol 300: C880-C887, 2011.
33. Schroeter H, Heiss C, Balzer J, Kleinbongard P, Keen CL, Hollenberg NK, Sies H, Kwik-Uribe C, Schmitz HH, and Kelm M. (-)-Epicatechin mediates beneficial effects of flavanol-rich cocoa on vascular function in humans. Proc Natl Acad Sci USA 103: 1024-1029, 2006.
34. Siddik ZH. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 22: 7265-7279, 2003.
35. Tanabe K, Lanaspa MA, Kitagawa W, Rivard CJ, Miyazaki M, Klawitter J, Schreiner GF, Saleem MA, Mathieson PW, Makino H, Johnson RJ, Nakagawa T. Nicorandil as a novel therapy for advanced diabetic nephropathy in the eNOS-deficient mouse. Am J Physiol Renal Physiol 302: F1151-F1160, 2012.
36. Taub PR, Ramirez-Sanchez I, Ciaraldi TP, Perkins G, Murphy AN, Naviaux R, Hogan M, Maisel AS, Henry RR, Ceballos G, Villarreal F. Alterations in skeletal muscle indicators of mitochondrial structure and biogenesis in patients with type 2 diabetes and heart failure: effects of epicatechin rich cocoa. Clin Transl Sci 5: 43-47, 2012.
37. Turrens JF. Superoxide production by the mitochondrial respiratory chain. Biosci Rep 17: 3-8, 1997.
38. Wang D, Lippard SJ. Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov 4: 307-320, 2005.
39. Watanabe N, Zmijewski JW, Takabe W, Umezu-Goto M, Le Goffe C, Sekine A, Landar A, Watanabe A, Aoki J, Arai H, Kodama T, Murphy MP, Kalyanaraman R, Darley-Usmar VM, Noguchi N. Activation of mitogen-activated protein kinases by lysophosphatidylcholineinduced mitochondrial reactive oxygen species generation in endothelial cells. Am J Pathol 168: 1737-1748, 2006.
40. Wei Q, Dong G, Franklin J, Dong Z. The pathological role of Bax in cisplatin nephrotoxicity. Kidney Int 72: 53-62, 2007.
41. Yamazaki KG, Romero-Perez D, Barraza-Hidalgo M, Cruz M, Rivas M, Cortez-Gomez B, Ceballos G, Villarreal F. Short-and long-term effects of (-)-epicatechin on myocardial ischemia-reperfusion injury. Am J Physiol Heart Circ Physiol 295: H761-H767, 2008.
42. Yamazaki KG, Taub PR, Barraza-Hidalgo M, Rivas MM, Zambon AC, Ceballos G, Villarreal FJ. Effects of (-)-epicatechin on myocardial infarct size and left ventricular remodeling after permanent coronary occlusion. J Am Coll Cardiol 55: 2869-2876, 2010.
43. Yang Z, Schumaker LM, Egorin MJ, Zuhowski EG, Guo Z, Cullen KJ. Cisplatin preferentially binds mitochondrial DNA and voltage-dependent anion channel protein in the mitochondrial membrane of head and neck squamous cell carcinoma: possible role in apoptosis. Clin Cancer Res 12: 5817-5825, 2006.